EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy

Gulcin Akinci iD, Javid Sardarzada iD, Haluk Topaloglu

Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1326-1333

DOI: 10.1177/22143602261433223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 07.04.2026. Verfasst von Gulcin Akinci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Neurology, Dr. Behcet Uz Children's Hospital, Izmir Faculty of Medicine, University of Health Science…. Hauptthemen laut MEDLINE: Thymidine Kinase, Mitochondrial Myopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thymidine kinase 2 (TK2) deficiency is an ultra-rare, severe mitochondrial myopathy caused by pathogenic variants in TK2 and characterized by a wide range of ages at onset. The infantile form, presenting before 2 years of age, is the most rapidly progressive and is associated with a high risk of early mortality. We describe the clinical outcomes of early nucleoside therapy in a series of children with infantile-onset TK2 deficiency.

Methods

We retrospectively reviewed four children with genetically confirmed infantile-onset TK2 deficiency treated with oral deoxycytidine/deoxythymidine (dC/dT) through an Early Access Program at two centers. Dosing was escalated to 800 mg/kg/day as tolerated. Patients were followed at baseline, Month 1, and regular intervals thereafter. Outcomes included neurological examinations, eight motor milestones, and respiratory and feeding support. Safety laboratory results, neuroimaging, and biopsy findings were reviewed.

Results

Treatment began at 19–24 months (median duration 26 months; range: 4–81). All presented within the first year with hypotonia, motor regression, and respiratory and/or bulbar involvement. Two required invasive ventilation and three required tube feeding before therapy. After dC/dT initiation, all improved with no further milestone loss. Three achieved independent ambulation and stair climbing; the fourth, at 4 months of therapy, has begun unassisted walking. Both tracheostomized patients were weaned from ventilation, and enteral feeding was discontinued in all three within 1–6 months. Only mild dose-related diarrhea occurred in one patient.

Conclusion

Early nucleoside therapy halts disease progression and restores motor function in infantile-onset TK2 deficiency, the most severe form of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymidine KinaseMitochondrial MyopathiesHumansInfantFemaleMaleRetrospective StudiesChild, PreschoolTreatment Outcome

Stichwörter der Autor:innen

infantile-onsetmitochondrial myopathymtDNA depletion syndromenucleoside therapythymidine kinase 2 deficiency

Substanzen

Thymidine Kinasethymidine kinase 2

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Neurology, Dr. Behcet Uz Children's Hospital, Izmir Faculty of Medicine, University of Health Sciences, Izmir, Turkey.
  • Department of Pediatrics, Division of Pediatric Neurology, Leyla Medical Center, Baku, Azerbaijan.
  • Interdisciplinary Neuroscience Department, Institute of Health Sciences, Bolu Abant İzzet Baysal University, Bolu, Turkey.
  • Department of Pediatrics, Division of Pediatric Neurology, Yeditepe University Faculty of Medicine, Istanbul, Turkey.

ORCID-Profile: Gulcin Akinci, Javid Sardarzada

Zitieren

APA

Akinci, G., Sardarzada, J., & Topaloglu, H. (2026). Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy. Journal of Neuromuscular Diseases, 13(6), 1326-1333. https://doi.org/10.1177/22143602261433223

Vancouver

Akinci G, Sardarzada J, Topaloglu H. Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy. Journal of Neuromuscular Diseases. 2026;13(6):1326-1333. doi:10.1177/22143602261433223

BibTeX
@article{Akinci2026,
  author = {Akinci, Gulcin and Sardarzada, Javid and Topaloglu, Haluk},
  title = {Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1326--1333},
  doi = {10.1177/22143602261433223}
}
Kostenlos starten →